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1. Introduction 
Left ventricular hypertrophy (LVH) is one of the vicious organ damages of essential 
hypertension. It contributes a lot to high mortality of essential hypertension due to sudden 
cardiac death, ventricular arrhythmia and heart failure. Multi-factors involve in the 
pathogenesis of hypertension-induced LVH including inherited variants as well as 
environmental factors. For the genetic influence, nucleus’ involvement has been discussed 
for years. However, much fewer interest has been put in the other inherited system—
mitochondrion. To make clear the relationship of mitochondria and LVH, we try to illustrate 
the clinical and pathological characteristics of LVH, the structure and function of 
mitochondria and mitochondrial role in LVH as follows: 
2. Left ventricular hypertrophy 
2.1 Definition, diagnostic standard, diversity in phenotypes 
Left ventricular hypertrophy (LVH) is a common complication of hypertension (the 
prevalence varies from 14 to 44% screening by echocardiography)[1] with multiple 
morphological and pathological characteristics which divide to subgroups as eccentric and 
concentric, asymmetric and symmetric hypertrophy according to heterogeneity in the 
pattern and extent of left ventricular wall thickening (see Fig. 1.)  
Echocardiography is often used as a sensitive screening and surveillance tool for LVH, 
especially to concentric and symmetric hypertrophy. Based upon a classic equation deduced 
by Devereux, R.B. (1987)[2]: 
 LV mass=1.04[(IVST+LVID+PWT)3-LVID3]0.001-13.6  
 BSA=0.006H+0.0128W-0.1529  
 LVMI=LVM/BSA  
Left ventricular mass index (LVMI) over 134g/m2 in men and above 110g/m2 in women are 
identified left ventricular hypertrophy.  
LVMI≤145 g/m2 is considered as mild, 145＜LVMI≤165 g/m2 as moderate, LVMI 
＞165g/m2 as severe[3]. Interventricular Septal Thickness(IVST)/Posterior wall 
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Thickness(PWT)≥1.3 is considered asymmetric hypertrophy; IVST/PWT≤1.3 identified 
symmetric; End Diastolic Diameter(EDD)＞50mm considered eccentric hypertrophy, 
EDD＜50mm identified concentric hypertrophy. In spite of diversity of phenotype LVH 
encompassed, the morbidity as well as mortality of cardiovascular events increase when 
induction of LVH.  
 
Fig. 1. Heterogeneity in the Pattern and Extent of Left Ventricular (LV) Wall Thickening in 
HCM Echocardiographic parasternal long-axis stop-frame images obtained in diastole 
showing A, massive asymmetric hypertrophy of ventricular septum (VS) with wall 
thickness >50 mm; B, pattern of septal hypertrophy in which the distal portion is 
considerably thicker than the proximal region at mitral valve level; C, hypertrophy sharply 
confined to basal (proximal) septum just below aortic valve (arrows); D, hypertrophy 
confined to LV apex (asterisk), consistent with the designation of apical hypertrophic 
cardiomyopathy (HCM); E, relatively mild hypertrophy in a concentric (symmetric) pattern 
with each segment of ventricular septum and LV free wall showing similar or identical 
thicknesses (paired arrows); F, inverted pattern of hypertrophy in which anterior VS is less 
substantially thickened than the posterior free wall (PW), which is markedly hypertrophied 
(i.e., 40 mm). Calibration marks are 1 cm apart. AO indicates aorta; AML, anterior mitral 
leaflet; and LA, left atrium. Reproduced from Maron BJ. Hypertrophic cardiomyopathy: a 
systematic review. JAMA. 2002, 287(10): 1308-20. 
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Fig. 2. M-mode echocardiogram of the left ventricle illustrating the standard measurement 
conventions. IVST= interventricular septal thickness; LVID= left ventricular internal 
dimension; PWT=posterior wall thickness ( Edited from Devereux, R.B. (1987) Detection of 
left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, 
standardization, and comparison to other methods. Hypertension., 9 (Suppl II)，II-19-II-26.) 
Essential hypertensive patients with left ventricular hypertrophy increase their mortality 
rates due to all cardiovascular events from 2 to 10 times more than hypertensives without 
signs of cardiac hypertrophy [4]. Serving as an independent predictor of cardiovascular 
events in patients with hypertension, LVH is also a prognostic indicator of hypertension. 
Patients with normal left ventricular geometry have the best prognosis, those with 
concentric remodeling or eccentric hypertrophy have intermediate, and those with 
concentric left ventricular hypertrophy are identified the worst prognosis [5].  
Given the fact that left ventricular hypertrophy is an end-organ stage of hypertension, 
scientists have been striving for the pathogenesis and reversal strategies of left ventricular 
hypertrophy for years. 
3. Genetic background 
3.1 Nuclear genes 
Plethoras of evidences support the hypothesis that multiple nuclear genes contribute to left 
ventricular hypertrophy[6]. It is identified that LVH is influenced by polygenic mutations 
susceptibility to hemodynamic disorders such as salt-sensitivity, obesity and insulin-
resistance etc. Brendan AI. reported a genetic locus on chromosome 2 of the spontaneously 
hypertensive rat affects relative LV mass independently of blood pressure [7].Yasuyuki 
Tsujita indicated both genes on chromosome 7 and 17 that influences LVM in a manner 
dependent on blood pressure [8]. Interestingly, left ventricular hypertrophy shared the same 
pathological changes with hypertrophic cardiomyopathy such as myocyte disarray, 
interstitial fibrosis and artery wall thickness. Moreover, hypertrophic cardiomyopathy can 
result from mutations in 11 genes that encode sarcomere proteins, loci where genes 
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encoding contractile, cytoskeletal, and calcium regulatory proteins. Thus, we can rule out 
the possibility of indicated genes contribute to hypertrophy cardiomyopathy involving in 
hypertension-induced left ventricular hypertrophy [9]. 
4. Mitochondrial and left ventricular hypertrophy 
4.1 mtDNA mutations 
In the early stage of hypertension-reduced LVH, ventricular hypertrophy is an important 
compensatory response to increased load, accompanied by increased amounts of 
mitochondria [10], which makes it likely that upregulation of cardiac energy production is a 
mechanism allowing increased cardiac work. However, the mitochondrial function is 
impaired and the efficiency of mtDNA ultimately decreases dramatically with time passing 
by. Then, the equilibrium between oxygen offering and consuming will be broken as 
mitochondrial energy under specific thresholds. The hypothesis of biogenesis of LVH has 
been supported by plethora of mtDNA mutations. Majamaa-Voltti K et al [11] reported that 
3243A>G mtDNA mutation is associated with LVH. Lin Z, et al [12] found G8584A mtDNA 
mutation may influence LVH in hypertensives. In particular, several point mutations such 
as G4284A [13], A4295G [14], A4269G[15], A4317G[15] and A4300G[16] located in tRNAIle 
contribute to hypertrophic cardiomyopathy to certain degree. A systematic and extended 
mutational screening for the mitochondrial genome has been initiated in a large cohort of 
Chinese population by the Geriatric Cardiology Clinic at the Chinese PLA General Hospital, 
Beijing, China. Specific mutations within the mitochondria were further evaluated. Changes 
of tRNAs were measured by northern blotting using nonradioactive digoxigenin (DIG)-
labeled oligodeoxynucleotides specific for each RNA. Rates of oxygen consumption in intact 
cells were determined with av YSI 5300 oxygraph. Sequence analysis of mitochondrial DNA 
in one Chinese pedigree identified a novel A-G transition at position 4401 (A4401G) at the 
junction of tRNAMet and tRNAGln. The non-coding region mutation appeared to affect the 
processing of precursors in these mitochondrial tRNAs. The reduction in the rate of 
respiration and marked decreases in the steady-state levels of tRNAMet and tRNAGln were 
detected in the cells carrying this mutation. The novel mutation was absent in 270 Chinese 
control subjects. In conclusion, the non-coding region (A4401G) mutation was involved in 
the pathogenesis of left ventricular hypertrophy in Chinese hypertensives[17]. 
MtDNA mutations can divide into rearrangement mutations and base substitutions. And 
base substitution mutations are subcategorized into missence mutations (protein coding 
genes alterations) and protein synthesis mutations (RNAs genes changes).  
4.2 Rearrangement mutations 
Rearrangements of mtDNA due to deletions or duplications generally occur in sporadic 
patients. Duplications are probably not directly pathogenic, but it produces deleted mtDNA 
molecules, which implicated into different diseases [18,19]. The most prominent multi-
systemic disorders involved in cardiomyopathy are Kearn-Sayre Syndrome (KSS) and 
Chronic Progressive External Ophthalmoplegia(CPEO) The characteristic symptoms of KSS 
are cardiac conduction block, cardiomyopathy and caridoembolic stroke with ocular 
damage including ophthalmoplegia, ptosis, pigmentary degeneration of retina. Compared 
with cardiac conduction blocks, cardiomyopathy is a much less frequent and late-onset 
symptom in KSS caused by the relatively low abundance of rearranged mtDNA molecules 
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in the myocardium. Fromenty and colleagues [20] demonstrated that duplications 
represented an unusually high proportion (41-91%) of all rearranged molecules in hearts 
from two KSS patients. Because of the preferential accumulation of duplicated rather than 
deleted mtDNA molecules, the cardiomyopathy may be relatively spared in KSS.CPEO is 
another rearrangement mtDNA mutation represents a series of abnormalities covering 
ocular myopathy, mitochondrial myopathy, renal failure and diabetes mellitus [21]. 
McComish M found the changes of hypertrophy via endomyocardial biopsy on light 
microscopy[22].   
4.3 Missence mutaions 
Leigh’s syndrome is a most severe missence mutation with neural, spinal and cardiac 
defects. Hypertrophic cardiomyopathy, as a kind of cardiac defect of Leigh’s 
syndrome，results from series of genes involving OXPHOS including MTAP6, NARP8993G 
and A3243G mutation[23]. Missence mutations in the gene that encodes Ǆ-2 regulatory 
subunit of the adenosine monophosphate-activated protein kinase(PRKAG2) have been 
reported to cause familial Wolff-Parkinson-White syndrome associated with conduction 
abnormalities and LVH [24,25]. 
4.4 Protein synthesis mutations 
Myoclonic epilepsy with ragged-red fibers (MERRF) is most frequently caused by an 
A8344G mutation in the tRNALys gene. In a review of 62 reported MERRF patients, about 
one third had clinical cardiomyopathy; 22% had Wolff-Parkinson-White syndrome[26]. 
Cardiac evaluation of two MERRF patients revealed asymmetric septal hypertrophy with 
diffuse hypokinesis of the left ventricle. [27] The G8363A mutation has been identified in two 
families with MERRF[28,29]. However, in two other families harboring this mutation, 
hypertrophic cardiomyopathy overshadowed the co-existing encephalopathy and hearing 
loss[30]. Another protein synthesis mutation is mitochondrial myopathy, lactic acidosis, 
stroke-like episode(MELAS) which accelerates the process of LVH secondary to 
vasculopathy[31]. After thorough review of database in Medline, we found that there are 16 
mitochondrial genes associated with hypertrophic cardiomyopathies derived from isolated 
or multisystemic disorder indicated in Table 1 . Thirteen point mutations are in tRNA genes, 
which do have very specific structural properties that allow an optimal positioning of 
signals for interaction with various partners such as the cognate aminoacyl-tRNA 
synthetases (the enzymes that charge the correct amino acid to the 3’ end of the specific 
tRNAs), translational initiation or elongation factors, and the ribosomal machinery. Three of 
these are tRNALeu(UUR) , tRNAIle and tRNALys, seem to be hot spots for cardiomyopathies. It 
is striking that most mutations in tRNAIle are associated with diseases that present primarily 
or exclusively with cardiomyopathy.A prime example of a tRNALeu(UUR) mutation associated 
with a multisystem disorder is A3243G, the most common cause of mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome[32,33]. In a 
review of 110 reported MELAS patients, cardiac manifestations included congestive heart 
failure in 18%, Wolff-Parkinson-White syndrome in 14%, and cardiac conduction block in 
6%[34].The cardiomyopathy is most commonly hypertrophic[35,36]. Atypical presentations of 
the A3243G mutation have included maternally inherited PEO with RRF and diabetes and 
deafness[37]. In addition, isolated cardiomyopathy can be the presenting manifestation of this 
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mutation.[38-40]. Three other point mutations in the tRNALeu(UUR) have been associated with 
cardiomyopathies alone (A3260G, C3303T), associated with myopathy (A3260G, C3303T), or 
as part of the MELAS syndrome (C3254G, A3260G) [38,41-46], The C4320T mutation was also 
associated with a multiorgan disorder in a child who died at age 7 months of cardiac failure 
with hypertrophic cardiomyopathy and a severe encephalopathy manifesting as seizures, 
nystagmus, and spastic tetraparesis[47]. Intriguingly, the three other point mutations in the 
tRNAIle gene, A4295G, A4300G, and A4317G, have been identified only in patients with 
isolated hypertrophic cardiomyopathies [15,48-49] . 
 
Mutation Gene Clinical features Reference 
A3243G 
C3254G 
A3260G 
C3303T 
A4269G 
G4284A 
A4295G 
A4300G 
A4317G 
C4320T 
A8344G 
G8363A 
G8584A 
T8993G 
T9997C 
G15243A 
 
tRNALeu(UUR) 
tRNALeu(UUR) 
tRNALeu(UUR) 
tRNALeu(UUR) 
tRNAIle 
tRNAIle 
tRNAIle 
tRNAIle 
tRNAIle 
tRNAIle 
tRNALys 
tRNALys 
ATPase 6 
ATPase 6 
tRNAGly 
Cyt b 
 
MELAS;PEO;DM/De; 
Cardiomyopathy(H) 
MELAS 
Myopathy/cardiomyopathy(H); 
MELAS 
Encephalocardiomyopathy(H) 
Cardiomyopathy(H) 
Encephalomyopathy; cardiomyopathy 
Cardiomyopathy(H) 
Cardiomyopathy(H) 
Cardiomyopathy(H+Di) 
Cardiomyopathy(H) 
Cardiomyopathy(H)/encephalopathy 
MERRF/De/Cardiomyopathy(H) 
Encephalopathy/cardiomyopathy(H), 
MERRF 
NARP/MILS; cardiomyopathy 
Cardiomyopathy(H)/GI dysmotility 
Cardiomyopathy(H) 
 
[32,33, 38,39] 
[41] 
[42,43] 
[44] 
[50] 
[13] 
[14] 
[16] 
[15] 
[47] 
[51] 
[29-31] 
[12] 
[52] 
[53] 
[54] 
 
AID, aminoglycoside-induced deafness; De, deafness; Di, dilated (cardiomyopathy); DM, diabetes 
mellitus; GI, gastrointestinal; H, hypertrophic cardiomyopathy; MELAS, mitochondrial 
encephaomyopathy, lactic acidosis, and strokelike episodes; MERRF, myoclonus epilepsy with 
raggedred fibers; MILS, maternally inherited Leigh syndrome; NARP, neuropathy, ataxia, retinitis 
pigmentosa; PEO, progressive external ophthalmoplegia; (Adatpted from Hirano M et al. Mitochondria 
and the heart. Current Opinion in Cardiology 2001, 16:201–210.) 
Table 1. Mitochondrial DNA point mutations associated with hypertrophic cardiomyopathy 
alone or as a major component of a multisystem disorder 
5. Defects in mtDNA function 
In prior reviews, we noted that several of the cardiomyopathy-associated point mutations in 
tRNA genes accumulated deficiencies in end maturation, including 3’ end cleavage by 
tRNAase Z and CCA addition by tRNA ucleotidyl-transferase, and in aminoacylation which 
affected Trna metabolism thus impaired the synthesis of protein in the end[55-58]. 
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Fig. 3. The tRNA end processing pathway followed by aminoacylation. (A) tRNA is 
transcribed as a precursor, with a 50 end leader and a 30 end trailer. (B) RNase P has 
endonucleolytically cleaved the tRNA at +1. (C) tRNAse Z endonucleolytically cleaves the 
precursor on the 30 side of the discriminator base (N; +73). (D) CCAadding enzyme (CCAse) 
adds CCA to the 30 end of the tRNA (N) produced by tRNase Z cleavage. (E) tRNA is 
charged with the cognate amino acid by a specific aminoacyl-tRNA synthetase (aaRS). 
Dashed line from CCA in (D) to tRNAse Z between (B) and (C) with an X through it 
indicates that 3’-CCA of mature tRNase Z anti-determinant. (Adapted from Levinger L, et 
al. Mitochondrial tRNA 3' end metabolism and human disease.Nucleic Acids Res. 
2004:11;32(18):5430-41.) 
The other genes situated in anticodon stem resulted in missense changes of mitochondria 
herein influence function of protein variably and implicated in pathogenesis of 
cardiomyopathy. Of these mtDNA mutations, OXPHOS, ROS and apoptosis, three basic 
function of mtDNA are estimated as culprits of LVH. 
6. Oxidative phosphorylation (OXPHOS) 
In the early stage of LVH, genes involved in energy transportation including electron 
transportation chain, tricarboxylic acid (TCA) cycle , glycolysis , fatty acid(FA) metabolism 
downregulate, while genes devoted to mitochondrial protein transportation and synthesis 
upregulate. As a result, the expression of cytoskeletal genes increases as well as fetal genes 
which in line with enhancement of left ventricular mass and size[59]. The compensatory LVH 
is associated with normalization of myocardial oxygen consumption at the expense of a 
decrease in the ratio between cardiac work and oxygen consumption (efficiency) [60]. With 
the time passing by, cardiac working efficiency decreases to a lowest level and heart failure 
occurs.   
7. Reactive oxidative species 
Since ETC is inhibited, the electrons accumulate in the early stage of the ETC-generating 
CoQ10H: This ubisemiquinone can then donate electrons directly to molecular oxygen (O2) 
to give superoxide anion(O2.-). Superoxide anion is detoxified by the mitochondrial 
manganese superoxide dismutase(MnSOD, EC 1.15.1.1) to give H2O2, and H2O2 is converted 
to H2O by glutathione peroxidase-1(EC1.11.1.9). H2O2, in the presence of reduced transition 
metals, can also be converted to the highly reactive hydroxyl radical (.OH). Reactive 
Oxidative Species potentially has both adaptive and maladaptive signaling consequences. 
Role of oxidative stress and nitric oxide synthase Growth initiators including angiotensin II, 
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ǂ-agonists, TNF-ǂ, and mechanical strain also promote the formation of reactive oxygen 
species (ROS) [61]. ROS hypertrophic response at low rates of ROS production to fibrosis [62] 
and myocyte death at high rates[63]. ROS formation is also stimulated by endothelial nitric 
oxide synthase (eNOS). In a transgenic eNOS knockout model with low ROS production, 
severely pressure-loaded hearts developed only modest concentric hypertrophy with little 
fibrosis and without left-ventricular cavity dilation.61 Consonant with overall knowledge[63], 
high rates of ROS production can thus contribute to the transition from left-ventricular 
hypertrophy to heart failure. Although these findings may be controversial [64], there has 
been recent confirmation of the concept [65]. Notably, plasma and pericardial markers of 
oxidative stress are increased in patients with chronic systolic failure of the left ventricle, 
with these increases related to the clinical severity of heart failure. Controversies in 
ventricular remodeling.[66] 
The chronic release of ROS has been recently linked to the development of left ventricular 
hypertrophy progression. The chronic release of ROS appears to derive from the 
nonphagocytic NAD(P)H oxidase and mitochondria. The experimental data are 
accumulating suggesting that abnormal activation of the nonphagocytic NAD(P)H oxidase 
in response to neurohormones (angiotensin II, norepinephrine, tumor necrosis factor-a) 
contribute to cardiac myocyte hypertrophy. In conclusion, the fibrosis, collagen deposition, 
and metalloproteinase activation involved in the remodeling of failing myocardium are 
dependent on ROS released. In animal model of chronic pressure overload, apoptosis has 
revealed as a pivotal trait of myocardial damage together with overproduction of 
extracellular matrix.  
8. Programme cell death 
Besides contractile disturbances of cardiomyocytes and interstitial and perivascular fibrosis, 
cardiomyocyte loss is now being considered as one of the determinants of the maladaptive 
processes implicated in the transition from compensated to decompensate left ventricular 
hypertrophy. A number of experimental evidence suggests that exaggerated apoptosis may 
account for the loss of cardiomyocytes in the hypertensive left ventricle. Furthermore, some 
factors intrinsic and extrinsic to the cardiomyocyte emerge as potential candidates to trigger 
apoptosis. Increased exposure of ROS accompany with decline in OXPHOS result in the 
opening of mtPTP, herein, apoptosis-initiated factors leak from inner membrane of 
mitochondrial to outer membrane. And apoptosis-related factors including procaspase and 
TNF-ǂ are activated which cause a series pathway of apoptosis[67].  
9. Variability of phenotypes in left ventricular hypertrophy 
Phenotype of LVH is variable even for a same mtDNA mutation due to multiple causes. 
First, diversity in frequency and efficiency of mitochondria transit from eggs to zygotes. The 
more mutated mitochondria inherited from mother eggs, the higher probability phenotype 
will present. Second, difference in mutation load within separated organs cause the 
diversity in phenotype. Cells will not lose their function until high load of pathogenic 
mtDNA mutations are present, ranging from 60% to 90%, symptoms arise once mutations 
over certain threshold and lead to impaired mitochondrial protein synthesis, as well as a 
severe respiratory chain deficiency. Third, variability of influences derived from nuclear 
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genome. Mitochondrial diseases may result from nuclear DNA mutation (Mendelian 
mutation) or mitochondrial mutation(maternal inheritance).Mitochondrial synthesis and 
function require estimated 1000 polypeptides, 37 of which are encoded by mitochondrial 
(mt) DNA, the rest by nuclear (n) DNA.The nuclear DNA background might also influence 
phenotypic expression of mtDNA polymorphisms. In fact, Arbustini and colleagues have 
demonstrated the coexistence of mutations in mtDNA and ǃ-myosin heavy chain (ǃMHC) in 
patients with hypertrophic cardiomyopathy, in which mtDNA mutations may contribute to 
the phenotypic variability of mendelian hypertrophic cardiomyopathies[68]. 
 
Fig. 4. Heteroplasmy: Mixed (heteroplasmic) populations of wild-type and mutant 
mitochondrial genomes are present. Filled circles indicate mutant mitochondrial genomes 
and open circles indicate wild-type. Thresholds: The thresholds for pathology are typically 
between 15 and 50% of mitochondrial tRNA function, affected by the extent of 
heteroplasmy. A lower functional level would be lethal and a higher level would be without 
a phenotype. (Adapted from Levinger L, et al. Mitochondrial tRNA 3' end metabolism and 
human disease.Nucleic Acids Res. 2004:11;32(18):5430-41.) 
10. Advances in therapy 
Reducing heart load, cutting off vicious cycle of hemodynamic disorders as well as thinning 
hypertrophic myocardium have been accepted as classic methods to treat LVH. As for the 
pathogenic involvement of mitochondria, gene therapy is a promising way to improve the 
outcome of treatment. Nevertheless, there’s no effective and consent methods to treat 
mitochondrial disorders so far. One process under way is to reduce the proportion of 
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mutated mtDNA to subthreshold levels. This could be achieved by adding more wild-type 
mtDNA, or by removing mutated mtDNA. At the experimental level, some contrary results 
derived from synthetic wild-type mtDNA transition and gene shifting in skeletal muscles, 
which help to draw a conclusion that an efficient approach to lead wild-type mtDNA to cells 
should be further investigated. To remove mutated mtDNA, one approach is to bind specific 
molecules to mutated mtDNA molecules and prevent them from replicating, while let wild-
type mtDNA replication to continue unimpeded. Another approach is to use drugs that 
select against mutated mtDNA in dividing cells, allowing wild-type mtDNA levels to 
increase. Otherwise, all the approaches with the goal letting the mutated cells down need to 
be tested from experimental stages to clinical usage [69]. Recently, antioxidants have been 
proposed to be important in the pathogenesis of mitochondrial disorders on the basis of 
ROS involvement [70]. Vitamin B, Vitamin C ,Vitamin E as well as Coenzyme Q has served as 
scavenger molecules and somewhat has been demonstrated to benefit patients with MELAS 
and Kearns-Sayre syndrome[71]. Although coenzyme Q10 has shown some early promise in 
Parkinson’s disease and Friedreich’s ataxia, such results can only be regarded as provisional 
at this stage. There have been no large-scale studies to determine the effectiveness of 
coenzyme Q10 in primary mtDNA diseases [72]. Other molecules involved in ETC may help 
offering materials for OXPHOS. Moreover, antiapoptosis drugs are beneficial to improving 
mtDNA diseases in line with the candidate of program cell death.  
11. Prospects 
Left ventricular hypertrophy is a hot spot for improving the life quality of patients with 
hypertension. The pathogenesis and progression of LVH are tightly linked to mitochondria 
as we stated above. However, the mechanism of mitochondria implicated into LVH still 
remain obscure that much more jobs are needed to disclose the secrets of relationship 
between mitochondria and left ventricular hypertrophy.1) which mtDNA mutation can be 
served as a marker to predict and indicate the prognosis of LVH? 2) How nDNA influence 
mtDNA, and to what extent can we use the methods protecting nDNA from damage to 
attain the role of protecting mtDNA. 3) What steps may we take to reduce frequency and 
quantity of mutated mtDNA thus cut off the deterioration pathways of LVH.   
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